ATE234864T1 - Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion - Google Patents

Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion

Info

Publication number
ATE234864T1
ATE234864T1 AT95940409T AT95940409T ATE234864T1 AT E234864 T1 ATE234864 T1 AT E234864T1 AT 95940409 T AT95940409 T AT 95940409T AT 95940409 T AT95940409 T AT 95940409T AT E234864 T1 ATE234864 T1 AT E234864T1
Authority
AT
Austria
Prior art keywords
site
superantagonists
interleukin
superagonists
human
Prior art date
Application number
AT95940409T
Other languages
English (en)
Inventor
Gennaro Ciliberto
Rocco Savino
Armin Lahm
Carlo Toniatti
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE234864T1 publication Critical patent/ATE234864T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
AT95940409T 1994-12-14 1995-12-13 Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion ATE234864T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM940805A IT1274782B (it) 1994-12-14 1994-12-14 Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
PCT/IT1995/000216 WO1996018648A1 (en) 1994-12-14 1995-12-13 Superagonists and antagonists of h il-6, and 3d modelling method for their selection

Publications (1)

Publication Number Publication Date
ATE234864T1 true ATE234864T1 (de) 2003-04-15

Family

ID=11402859

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940409T ATE234864T1 (de) 1994-12-14 1995-12-13 Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion

Country Status (13)

Country Link
US (2) US5849283A (de)
EP (1) EP0745094B1 (de)
JP (2) JP3206919B2 (de)
CN (1) CN1070866C (de)
AT (1) ATE234864T1 (de)
AU (1) AU702783B2 (de)
CA (1) CA2177838A1 (de)
DE (1) DE69529973T2 (de)
DK (1) DK0745094T3 (de)
ES (1) ES2192585T3 (de)
IT (1) IT1274782B (de)
PT (1) PT745094E (de)
WO (1) WO1996018648A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871472A4 (de) * 1995-10-27 2001-05-30 Amrad Operations Pty Ltd Cytokine und ihre verwendung in behandlung und/oder vorbeugung von brustkrebs
CA2237114A1 (en) * 1995-11-07 1997-05-15 Kaneka Corporation Autoantigens
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
AUPO439396A0 (en) * 1996-12-24 1997-01-23 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment and prophylaxis
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
EP2322216A1 (de) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha Präventives oder therapeutisches Mittel mit einem IL-6-Antagonisten als Wirkstoff für durch sensibilisierte T-Zellen vermittelte Erkrankungen
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
EP1094831A4 (de) 1998-07-06 2004-11-03 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur (in vitro) fertilisation
JP4799516B2 (ja) * 1998-08-24 2011-10-26 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤
ES2276525T3 (es) 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
AU7078200A (en) 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
CN1630514A (zh) 2001-12-05 2005-06-22 贝勒医学院 通过调节交感神经紧张性控制骨形成的方法和组合物
WO2004073741A1 (ja) 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
MXPA06003768A (es) 2003-10-17 2006-06-23 Chugai Pharmaceutical Co Ltd Agente terapeutico para el mesotelioma.
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
TWI438208B (zh) 2007-01-23 2014-05-21 中外製藥股份有限公司 抑制慢性排斥反應之藥劑
CA2728243C (en) 2008-06-05 2020-03-10 Chugai Seiyaku Kabushiki Kaisha Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
EP2898896A1 (de) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Mittel zur Verwendung bei der Behandlung von Netzhautentzündung
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
EP3957324A4 (de) 2019-04-17 2023-02-08 Hiroshima University Therapeutikum für die urologische onkologie, dadurch gekennzeichnet, dass es in kombination mit il-6 -inhibitor und ccr2 -inhibitor verabreicht wird

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009138A1 (en) * 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
IT1263022B (it) * 1992-11-06 1996-07-23 Angeletti P Ist Richerche Bio Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica.

Also Published As

Publication number Publication date
WO1996018648A1 (en) 1996-06-20
ITRM940805A1 (it) 1996-06-14
CN1140456A (zh) 1997-01-15
DE69529973T2 (de) 2003-12-04
US5849283A (en) 1998-12-15
EP0745094B1 (de) 2003-03-19
PT745094E (pt) 2003-07-31
JPH09502460A (ja) 1997-03-11
DK0745094T3 (da) 2003-06-10
ITRM940805A0 (it) 1994-12-14
AU4187196A (en) 1996-07-03
JP3206919B2 (ja) 2001-09-10
CA2177838A1 (en) 1996-06-15
EP0745094A1 (de) 1996-12-04
AU702783B2 (en) 1999-03-04
US5914106A (en) 1999-06-22
JP2001354698A (ja) 2001-12-25
DE69529973D1 (de) 2003-04-24
IT1274782B (it) 1997-07-24
CN1070866C (zh) 2001-09-12
ES2192585T3 (es) 2003-10-16
HK1011032A1 (en) 1999-07-02
JP3286310B2 (ja) 2002-05-27

Similar Documents

Publication Publication Date Title
DE69529973D1 (de) Superagonisten und Antagonisten von Humanen IL-6 und Methoden zu deren Selektion
EP0890642A3 (de) Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE69636720D1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
EP0959074A3 (de) Substituierte Pyrazole als CRF Antagonisten
NO891711L (no) Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr.
ES535842A0 (es) Un procedimiento para preparar octapeptidos lineales
DE69519748D1 (de) Aus den vorstufen des mage tumor-abstossungsantigen abstammende einzelne peptede, die hla-a2 moleküle komplexieren
GR3033111T3 (en) A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130.
Tanigaki et al. Identity of the HL-A common portion fragment and human β2-microglobulin
PT1148065E (pt) Proteínas de fusão
ES8602617A1 (es) Un procedimiento para la produccion de peptidos.
ATE8988T1 (de) Lh-rh antagonisten.
DK0876610T3 (da) Fremgangsmåde og anvendelse af polypeptid i sædcelle-æg-binding til at foröge eller mindske fertilitet
DE69939586D1 (de) Inhibitoren für die gefässneubildung
DE69932804D1 (de) Protein, welches durch einen cystinknoten charakterisiert ist und verfahren zu dessen herstellung
DK0977859T3 (da) Den neurotrofiske faktor NNT-1
MOBERG Is the Pacific an area of speciation for some foliose genera of the lichen family Physciaceae?
DE59207008D1 (de) Klonierung eines neuen mitgliedes der familie der fibroblasten-wachstumsfaktoren (fgf)-rezeptoren
Alekseeva et al. Chemical fragmentation by o-iodosobenzoic acid of alpha-chain of histidine decarboxylase from Micrococcus sp. n. AT tryptophan residues.
Fitch et al. Multiple lymphokine activities are secreted by a cloned murine T helper cell
Altman et al. Construction of T-cell hybridomas secreting distinct antigen-nonspecific lymphokines
Weibull Resistance in the genera Avena and Hordeum to the aphid Rhopalosiphum padi (L.)--genetic resources and nutritional aspects.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0745094

Country of ref document: EP

REN Ceased due to non-payment of the annual fee